BIOGEN INC. DL -,0005 | 220.000 / -0.25% |
Date/Time | 01/22 / 22:59 |
Chg. / Chg.(%) | -0.550 / -0.25% |
Bid | 220.000 |
Ask | 221.150 |
Open | 220.550 |
Previous Close | 220.550 |
High | 224.700 |
Low | 219.700 |
Volume [EUR] | - |
Volume [Units] | |
Price fixings | 5902 |
ISIN | US09062X1037 |
Security | IDP |
Exchange | Lang & Schwarz |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
NASDAQ | 269.4400 | ![]() |
691,106 |
IEX | 269.37 | ![]() |
36,610 |
Cboe US | 269.57 | ![]() |
24,969 |
London Inter.. | 270.23 | ![]() |
1,739 |
Xetra | 221.10 | ![]() |
1,633 |
TradeGate | 221.600 | ![]() |
1,166 |
Stuttgart | 220.100 | ![]() |
115 |
Frankfurt | 220.9500 | ![]() |
68 |
Vienna Globa.. | 221.15 | ![]() |
51 |
München | 222.10 | ![]() |
10 |
gettex | 221.500 | ![]() |
5 |
Hamburg | 220.60 | ![]() |
0 |
Düsseldorf | 221.65 | ![]() |
0 |
Berlin | 222.10 | ![]() |
0 |
Hannover | 220.60 | ![]() |
0 |
Lang & Schwa.. | 220.000 | ![]() |
|
Mexico | 5,375.00 | ![]() |
20 |
News
- Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone
01/11/2021 / 13:30 - GlobeNewswire - Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec)
01/08/2021 / 13:30 - GlobeNewswire - The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Relapsing-Remitting Multiple Sclerosis
12/21/2020 / 13:30 - GlobeNewswire - Biogen agrees to $22M settlement to resolve claims on illegal business
12/17/2020 / 20:04 - TeleTrader - Biogen Files New Drug Application for Aducanumab in Japan
12/10/2020 / 04:30 - GlobeNewswire